We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

This study has been terminated.
(Portfolio consolidation.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00893516
First Posted: May 6, 2009
Last Update Posted: February 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Emergent BioSolutions
  Purpose
Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.

Condition Intervention Phase
T-cell Lymphoma Biological: CHOP + CD4 Drug: CHOP Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.

Resource links provided by NLM:


Further study details as provided by Emergent BioSolutions:

Enrollment: 5
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
CHOP chemo therapy + CD4 therapy
Biological: CHOP + CD4
Active Comparator: 2
CHOP chemotherapy
Drug: CHOP

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • study is closed to enrollment

Exclusion Criteria:

  • study is closed to enrollment
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Emergent BioSolutions
ClinicalTrials.gov Identifier: NCT00893516     History of Changes
Other Study ID Numbers: GEN112
First Submitted: May 5, 2009
First Posted: May 6, 2009
Last Update Posted: February 26, 2013
Last Verified: February 2013

Keywords provided by Emergent BioSolutions:
non cutaneous peripheral t-cell lymphoma with nodal involvement

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin